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Summary
Activated p38 MAPK alpha (pp38α) is a good prognostic marker in pancreatic ductal 
adenocarcinoma (PDAC) that could be used to personalize therapy. pp38α suppresses JNK-
mediated proliferation, both in vitro and in vivo. The current findings support testing of 
combination therapies that include JNK targeting and/or suppressing negative regulators of pp38α.
In this issue of Clinical Cancer Research, Zhong and colleagues (1) performed biomarker 
profiling to identify survival-predicting pathways in resectable pancreatic ductal 
adenocarcinoma (PDAC). Using tissues obtained from 36 patients through a rapid autopsy 
program, they prepared a discovery set consisting of a tissue microarray (TMA) of primary 
and metastatic lesions (Fig. 1A). Markers were grouped into three clusters: 1) biomarkers 
with abnormal immunostaining patterns when compared to normal epithelial cells within the 
same sections (cluster 1); 2) biomarkers with expression heterogeneity (cluster 2); and 3) 
biomarkers with similar patterns of expression intensity or cellular localization to normal 
epithelial cells. The authors focused on the 12 proteins in cluster 2, all of which have been 
implicated in PDAC pathobiology: β-catenin, cyclin D1, EGFR, mesothelin, MUC5AC, p53, 
p63, phospho-p38 MAPK (pp38), phospho-JNK (pJNK), phospho-AKT, S100A2, and YAP. 
They next prepared five TMAs from 83 resected PDACs (Fig. 1A) and determined that 
cytoplasmic pp38 overexpression in the cancer cells correlated with significantly prolonged 
survival (24.4 months) vs. the low expression group (14.7 months), and with decreased 
lymph node involvement.
Interestingly, 41 of the 83 resected patients completed a course of adjuvant therapy, 
consisting of 1-2 cycles of gemcitabine followed by 5-FU and radiation therapy, followed by 
another 2-4 months of gemcitabine. Patients whose cancers exhibited high pp38 scores had a 
longer overall survival (28.4 months) vs. the low expression group (15.0 months). In another 
group of 26 patients treated according to a similar protocol (RTOG 97-04), high pp38 
expression was an independent predictor of improved patient survival. Together, these 
observations support the conclusion that pp38 is a prognostic marker in PDAC, and 
Corresponding author: Murray Korc, M.D., Indiana University School of Medicine, 980 W. Walnut Street, Indianapolis, IN 46202, 
Phone: 317-278-6410, Fax: 317-274-8046, mkorc@iu.edu. 
Disclosure of Potential Conflicts of Interest
There are no potential conflicts of interest.
NIH Public Access
Author Manuscript
Clin Cancer Res. Author manuscript; available in PMC 2015 December 01.
Published in final edited form as:
Clin Cancer Res. 2014 December 1; 20(23): 5866–5868. doi:10.1158/1078-0432.CCR-14-1543.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
underscore the usefulness of TMA analysis using well-annotated patient samples obtained 
through a rapid autopsy program.
PDAC is a deadly cancer that is remarkably recalcitrant to chemotherapy and radiation 
therapy (2). Multiple features contribute to therapeutic resistance. These include the 
overexpression of growth factors and their respective high-affinity receptors, excessive 
production of cytokines, a desmoplastic microenvironment with areas of hypoxia and 
attenuated/leaky vascular perfusion, a plethora of molecular alterations that include mutated 
Kras in 95% of PDAC patients, aberrant non-coding RNA expression, and suppression of 
cancer-directed immune mechanisms (3-5). Consequently, PDAC exhibits complex 
signaling cascades and loss of negative growth constraints. For example, there are four p38 
mitogen activated protein kinases (MAPKs) encoded by four genes (6). MAPK11 encodes 
p38β, MAPK12 encodes p38γ, and MAPK13 encodes p38δ, whereas MAPK14 encodes 
p38α, which was the focus of the current study. Other members of this family include the 
ERK1 and ERK2 MAPKs that are activated by mitogenic growth factors and three JNKs (7). 
JNK1 is encoded by MAPK8, whereas JNK2 and JNK3 are encoded by MAPK9 and 
MAPK10, respectively. JNK1 and JNK2 are ubiquitous, but JNK3 is mostly expressed in the 
brain. These pathways are often depicted in a modular and highly structured manner in 
which a MAPK kinase kinase (MAP3K) such as Raf activates a MAPK kinase (MAP2K) 
such as MEK, which in turn activates a MAPK such as ERK1 (Fig. 1 B). However, the 
context-dependence of the actions of different MAPKs, the multiplicity of MAP3Ks and 
MAP2Ks, their ability to cross-talk, and the fact that these pathways are modulated by 
multiple cytokines, growth factors, and negative signals such as phosphatases has stymied 
previous efforts to assess the exact role of pp38 in PDAC.
To delineate the mechanisms whereby pp38 exerts its protective actions, Zhong and 
colleagues studied seven recently derived human pancreatic cancer cell lines. Three of these 
cell lines (Panc5.04, A10.7 and A38.44) expressed pp38 and its downstream target phospho-
ATF2 (pATF2), suggesting that pp38 was active in these cells. They next used three distinct 
p38 inhibitors (SB202190, SB203580 and SB239063) and determined that all three 
pyridinyl imidazoles enhanced cell proliferation and decreased pATF2 levels, confirming 
the presence of active pp38 in these cells. However, these inhibitors do not exert completely 
superimposable effects, and they exhibit off-target actions at high concentrations. 
Nonetheless, subsequent experiments with 10 μM SB202190 revealed that inhibition of 
pp38 led to enhanced proliferation under both normoxic and hypoxic conditions, indicating 
that pp38 suppressed pancreatic cancer cell proliferation even in circumstances that mimic 
the pancreatic tumor microenvironment.
SB202190 also increased pJNK levels in Panc5.04, A10.7 and A38.44 cells, whereas pJNK 
inhibition by SP600125 blocked the growth-stimulatory effects of p38 inhibition. 
Classically, JNKs and p38 MAPKs are activated by MKK4/7 and MKK3/6, respectively 
(Fig. 1B). However, MKK4 can also activate p38α, which in turn can inhibit MKK4/7 
through a complex negative feedback loop. Zhong and colleagues determined that MKK7 
phosphorylation, and hence activation, increased in all three cell lines as a consequence of 
p38 inhibition by SB202190. They next demonstrated that siRNA-mediated suppression of 
MKK7 markedly attenuated the proliferative actions of SB202190. Thus, both SP600125-
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mediated JNK inhibition and si-RNA-mediated knockdown of MKK7 prevented SB202190-
induced proliferation, confirming that pp38-mediated growth-inhibitory effects in PDAC are 
due to its ability to suppress pJNK proliferative actions.
Zhong and colleagues next tested the effects of SB202190 and SP600125 in a subcutaneous 
xenograft model, using Panc5.04 and A10.7 cells expressing pp38, and A2.1 and A6L cells 
that express very low levels of either pp38 or pJNK. In tumors derived from Panc5.04 and 
A10.7 cells, inhibition of pp38 resulted in enhanced growth, whereas pJNK inhibition with 
SP600125 attenuated growth. By contrast, tumors derived from A2.1 and A6L cells were not 
affected by either inhibitor. Although the studies were not performed in an orthotopic model 
that could have provided information on metastases, these observations indicate that pp38 
signaling is not only a predictive marker of outcome in resected PDAC, but is also a 
protective tumor suppressor that antagonizes the deleterious actions of JNK.
This study is important for several reasons. First, the finding that pp38 is a favorable 
prognostic marker in PDAC is a major discovery, given the pivotal role of MAPKs in PDAC 
pathobiology and the complexity of these signaling pathways. Second, the study suggests 
that pp38 may be a biomarker delineating when adjuvant radio-chemotherapy would be 
beneficial in resected PDAC patients, which would be useful clinically given previous 
negative results with this therapeutic approach (8). Third, p38 activation has been previously 
shown to attenuate cell proliferation by such diverse mechanisms as suppressive effects at 
both the G1/S and G2M transitions, inhibition of EGF receptor signaling and ERK1/2 
activation, antagonizing pJNK actions and upregulating p53 activity (9). However, this is the 
first demonstration that pp38 acts as a tumor suppresser in PDAC by inhibiting JNK actions. 
Fourth, it is now possible to consider additional pre-clinical studies followed by 
personalized therapy trials based on targeting JNK, which is activated downstream of 
oncogenic Kras in PDAC and which promotes the self-renewal of cancer stem cell like cells 
thereby sustaining their role in tumor initiation (10).
Future studies should delineate why and how p38α becomes activated in PDAC, whether it 
is possible to activate p38α in those cancers where it is not active, and how various p38 and 
JNK isoforms differ in their actions in PDAC. It will also be important to determine whether 
it is possible to target JNK more efficiently and to suppress the actions of negative 
regulators of pp38 such as DUSP1/ MKP1 which inactivates pp38 and enhances 
tumorigenicity and chemoresistance in PDAC (11-12).
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Figure 1. 
Uncovering phospho-p38 MAPK as a good prognostic marker that suppresses JNK-induced 
mitogenesis in pancreatic cancer. A. A discovery tissue microarray (TMA) and a validation 
TMA were used to identify increased phospho-p38 MAPK (pp38) as a good prognostic 
marker in PDAC. B. Schematic representation of MAPK signaling pathways. Stress 
pathways, growth factors, and cytokines can activate MAPK signaling. The indicated 
MAPK kinase kinases (MAP3Ks) activate MAPK kinases (MAP2Ks), which activate 
MAPKs, as explained in the text. In general MKK4/7 activate JNKs, whereas MKK3/6 
activate p38 MAPKs. In addition, MKK4 can activate p38 MAPK alpha (p38α). Activated 
p38α (pp38α) can in turn inhibit MKK4/7, thereby blocking JNK activation and abrogating 
its growth-stimulatory actions. In addition, activated p38α can suppress mitogenic signaling 
through other mechanisms as discussed in the text.
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